Loading...
Market
How many additional participants will be involved in new studies by October 2025?
2
Resolution / Starting Odds
Less than 50 • 25%
50 to 100 • 25%
101 to 200 • 25%
More than 200 • 25%
Clinical trial registries and research publications
Story
Study Shows First-of-Its-Kind Glaucoma Treatment and Retina Implant Improves Reading Ability in 38 Blind Participants
Oct 29, 2024, 11:50 AM
Recent research has demonstrated promising advancements in vision restoration for individuals with severe vision loss. A study involving 38 participants who were legally blind showed that a tiny chip, functioning as a replacement retina, was successfully implanted. Preliminary results indicated a significant enhancement in the participants' ability to read an eye exam scale. This innovative approach marks a potential breakthrough in glaucoma treatment, with the first-of-its-kind therapy now being utilized in Massachusetts. Researchers noted that this is the first instance of restoring the ability to read fluently among blind patients, highlighting the significance of these findings in the field of ophthalmology.
View original story
Similar markets
1-2 • 25%
3-4 • 25%
5-6 • 25%
7 or more • 25%
0-10 • 25%
11-20 • 25%
21-30 • 25%
31 or more • 25%
1-3 • 25%
4-6 • 25%
7-9 • 25%
10 or more • 25%
More than 10 studies • 25%
5-10 studies • 25%
1-4 studies • 25%
No studies • 25%
Yes • 50%
No • 50%
0-2 • 25%
3-4 • 25%
5-6 • 25%
Trial not completed • 25%
0-5 sites • 25%
6-10 sites • 25%
11-15 sites • 25%
16-20 sites • 25%
0-1000 • 25%
1001-2000 • 25%
2001-3000 • 25%
3001+ • 25%
0-5 trials • 25%
6-10 trials • 25%
11-15 trials • 25%
More than 15 trials • 25%
0-2 studies • 25%
3-5 studies • 25%
6-8 studies • 25%
More than 8 studies • 25%
0-2 trials • 25%
3-5 trials • 25%
6-8 trials • 25%
More than 8 trials • 25%
0-5 trials • 25%
6-10 trials • 25%
11-15 trials • 25%
More than 15 trials • 25%